T
MRNA icon

TOBAM’s Moderna MRNA Stock Holding History

TOBAM’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$627K Buy
8,956
+3,826
+75% +$198K 0.15% 130
2026
Q1 		$261K Sell
5,130
-41,059
-89% -$1.92M 0.07% 179
2025
Q4 		$1.36M Sell
46,189
-25,609
-36% -$696K 0.33% 78
2025
Q3 		$1.85M Sell
71,798
-28,497
-28% -$795K 0.67% 53
2025
Q2 		$2.77M Buy
100,295
+55,542
+124% +$1.46M 1.08% 38
2025
Q1 		$1.27M Buy
44,753
+19,208
+75% +$682K 0.54% 58
2024
Q4 		$1.06M Sell
25,545
-2,249
-8% -$107K 0.32% 74
2024
Q3 		$1.86M Buy
27,794
+15,249
+122% +$1.4M 0.34% 69
2024
Q2 		$1.49M Sell
12,545
-55,983
-82% -$7.08M 0.23% 79
2024
Q1 		$7.3M Sell
68,528
-66,579
-49% -$6.71M 0.65% 46
2023
Q4 		$13.4M Sell
135,107
-27,821
-17% -$2.34M 1.18% 36
2023
Q3 		$16.8M Buy
162,928
+2,228
+1% +$249K 1.35% 31
2023
Q2 		$19.5M Buy
160,700
+16,629
+12% +$2.22M 1.47% 28
2023
Q1 		$22.1M Buy
144,071
+11,345
+9% +$1.87M 1.46% 30
2022
Q4 		$23.8M Sell
132,726
-18,526
-12% -$3.03M 1.58% 24
2022
Q3 		$17.9M Buy
151,252
+4,481
+3% +$680K 1.25% 28
2022
Q2 		$21M Sell
146,771
-7,406
-5% -$1.06M 1.31% 25
2022
Q1 		$26.6M Buy
154,177
+60,818
+65% +$10.2M 1.34% 25
2021
Q4 		$23.7M Buy
93,359
+12,915
+16% +$3.78M 1.07% 34
2021
Q3 		$31M Sell
80,444
-81,233
-50% -$30M 1.31% 30
2021
Q2 		$38M Sell
161,677
-75,355
-32% -$13.5M 1.52% 23
2021
Q1 		$31M Sell
237,032
-33,440
-12% -$4.85M 1.32% 31
2020
Q4 		$28.3M Sell
270,472
-168,885
-38% -$17.1M 1.26% 30
2020
Q3 		$31.1M Buy
439,357
+43,903
+11% +$3.06M 1.56% 25
2020
Q2 		$25.4M Buy
+395,454
New +$21.7M 1.63% 27

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

TOBAM's MRNA Position: Q2 2026 in Review

TOBAM increased its Moderna (MRNA) stake by 75% in Q2 2026, buying an estimated $198K and bringing the position to 8,956 shares worth $627K. The position accounts for 0.15% of the portfolio, ranked #130.

TOBAM first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $38M in Q2 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • TOBAM held 8,956 shares of Moderna worth $627K as of Q2 2026.
  • TOBAM bought 3,826 Moderna shares in Q2 2026, an estimated $198K.
  • Moderna made up 0.15% of TOBAM's portfolio in Q2 2026, its #130 holding.
  • TOBAM first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • TOBAM's Moderna position peaked at $38M in Q2 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on TOBAM's 13F filing for Q2 2026, filed 31 Jul 2026.